G
Gerwyn
Guest
I'm not sure what you mean here. It has nothing to do with anything I brought up. Perhaps you are commenting on another post...not sure.
.
Again, nothing to do with what I said. The paper I quoted was about Detailing, gabapentin just happened to be the drug in the study because there was abundant documentation available resulting from an FOI request(re detailing...not the drug per se). Of course that is made very clear in the paper, so I'm sure you picked that up when you read it[?]
No. They are not. That is the point.
Please read the papers I cited. Otherwise I don't see the point in commenting.
Here are the salient points;
Of approx 70 applications for FDA approval studies, all were completed but less than half were published. The only ones published were the ones in which the antidepressant performed better than placebo. More than 50%, which were not published had placebo outperforming the antidepressant.
It was based on these studies that next gen. antidepressants have been approved. It is also the basis on which the more recent theories you are bringing up are founded.
This is a very simple synopsis, the complete story is quite a bit worse.
Ok their sampling was biased they did not look at the big prospective studies over the last ten years .you can make meta analysis say virtually whatever you want them to say if you are selective with their data and use the "right" statistical tools.They did both.i read your studies and analysed them.No medic in the UK takes any notice of meta analysis to back up any scientific claim.You need prospective studies.The gabapentin article was a marketing report the like of which i,ve seen many times before 1995 come on!What doctors say when they are being paid to complete surveys and the reality of practice are completely different
There are many reasons why a study is requested by a regulatory authority in phase 1 2 and 3. They are mostly concerned with safety pharmaco kinetics LD 50 and so on.They are almost never published.The authors do not appear to be able to tell classes of antidepressants apart --prozac is hardly a new class I note they did not referr to the older and very cheap monoamine oxidase inhibitors and so on--Why was this "study" carried out?Please dont think that I disagree with you about the nefarious practices within pharma because I do.But we cant rely on studies of this quality to support our(legitamate) arguments when we would severly critise this methodology if used against us..The work on neurogenesis was first carried out re research into the dissociative symptoms in PTSD and nothing to do with depression whatsoever.I promise i will try to find it
people do use gaba pentin off liscence occasionaly because of desperation but its main use is per license because it is very toxic.Experience refutes the detailing theory, that is essentially my point if clumsily put